148 related articles for article (PubMed ID: 1503898)
1. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro.
Melvik JE; Dornish JM; Pettersen EO
Br J Cancer; 1992 Aug; 66(2):260-5. PubMed ID: 1503898
[TBL] [Abstract][Full Text] [Related]
2. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde.
Dornish JM; Melvik JE; Pettersen EO
Anticancer Res; 1986; 6(4):583-8. PubMed ID: 3752939
[TBL] [Abstract][Full Text] [Related]
3. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
Melvik JE; Pettersen EO
Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of cis-dichlorodiammineplatinum (II)-induced cytotoxicity by methylglyoxal.
Dornish JM; Pettersen EO
Anticancer Res; 1989; 9(4):1137-42. PubMed ID: 2817795
[TBL] [Abstract][Full Text] [Related]
5. Increase in cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells.
Melvik JE; Pettersen EO; Gordon PB; Seglen PO
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1523-30. PubMed ID: 3595677
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.
Dornish JM; Pettersen EO; Oftebro R
Br J Cancer; 1987 Sep; 56(3):273-8. PubMed ID: 3663475
[TBL] [Abstract][Full Text] [Related]
7. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
8. Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells.
Dornish JM; Pettersen EO; Oftebro R
Cancer Res; 1989 Jul; 49(14):3917-21. PubMed ID: 2736532
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cis-dichlorodiammineplatinum(II)-induced cytotoxicity by benzaldehyde derivatives.
Dornish JM; Pettersen EO
Cancer Lett; 1989 Jul; 46(1):63-8. PubMed ID: 2736510
[TBL] [Abstract][Full Text] [Related]
11. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
12. Effect of cis- and trans-dichlorodiammineplatinum(II) on human tumor cell proliferation in diffusion chambers in vivo.
Ambrose KR; Lowrey JS
Cancer Res; 1982 May; 42(5):1769-73. PubMed ID: 7039818
[TBL] [Abstract][Full Text] [Related]
13. Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups.
Dornish JM; Pettersen EO
Cancer Lett; 1985 Dec; 29(3):235-43. PubMed ID: 4075292
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).
Viale M; Cafaggi S; Parodi B; Esposito M
Cancer Chemother Pharmacol; 1995; 35(5):371-6. PubMed ID: 7850917
[TBL] [Abstract][Full Text] [Related]
15. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
16. Interaction between the kinetics of thermotolerance and effect of cis-diamminedichloroplatinum(II) or bleomycin given at 37 or 43 degrees C.
Majima H; Kashiwado K; Egawa S; Suzuki N; Urano M
Int J Hyperthermia; 1992; 8(4):431-42. PubMed ID: 1383358
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cis-dichlorodiammineplatinum-induced cell inactivation by benzaldehyde.
Dornish JM; Pettersen EO; Oftebro R; Melvik JE
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1287-93. PubMed ID: 6541584
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
19. Requirement of a reactive aldehyde moiety for aldehyde-mediated protection against cis-dichlorodiammineplatinum-induced cell inactivation.
Dornish JM; Pettersen EO
Biochem Pharmacol; 1990 Jan; 39(2):309-18. PubMed ID: 2302256
[TBL] [Abstract][Full Text] [Related]
20. In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb (2H) on cis-diamminedichloroplatinum (II)-induced cytotoxicity.
Melvik JE; Dornish JM; Larsen RO; Børretzen B; Oftebro R; Pettersen EO
Anticancer Res; 1992; 12(1):33-8. PubMed ID: 1567178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
